一阶段随机双盲研究,研究一种针对HSD17B13的RNA干扰治疗方法,用于与代谢功能障碍相关的脂肪肝炎
Arun J Sanyal1, Jorg Taubel2, Prajakta Badri3
1Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, USA.
Journal of hepatology
|June 28, 2025
概括
拉皮罗西兰是一种针对HSD17B13的新疗法,在I期研究中显示出良好的安全性. 它显著降低了HSD17B13肝脏mRNA在患有代谢功能障碍相关的脂肪肝炎 (MASH) 的患者.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学是一种遗传学.
背景情况:
- 在HSD17B13中功能丧失的变体与较低的慢性肝病风险有关.
- HSD17B13基因在MASH的发病过程中发挥着作用.
- 拉皮罗西兰向肝脏HSD17B13mRNA用于MASH治疗.
研究的目的:
- 评估拉皮索西兰的安全性,耐受性,药理动力学和药理动力学.
- 评估拉皮索西兰对肝脏HSD17B13mRNA表达的影响.
- 确定拉皮罗西兰作为MASH治疗药物的潜力.
主要方法:
- 第一个阶段,随机,双盲,安慰剂控制,多中心研究 (ALN-HSD-001).
- 部分A:健康成年人的单次上升剂量. 部分B:在MASH患者中分隔12周的两个剂量.
- 肝脏活检用于HSD17B13mRNA测量;主要终点:不良事件.
主要成果:
- 拉皮罗西兰证明了良好的安全性和耐受性;注射部位反应是轻微的和短暂的.
- 没有观察到与治疗相关的严重不良事件或药物诱导的肝损伤.
- 肝脏HSD17B13mRNA的剂量依赖性减少,最高剂量组在6个月内平均减少78%.
结论:
- 拉皮洛西兰显示出令人鼓舞的安全性和耐受性概况.
- 拉皮洛西兰可以大大降低肝脏HSD17B13mRNA的表达.
- 数据支持进一步开发用于MASH治疗的Rapirosiran.
更多相关视频
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
8.0K
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12.1K
相关概念视频
Experimental RNAi
6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
RNA Interference
26.5K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.5K
siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
